Overview

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

Status:
Completed
Trial end date:
2012-12-23
Target enrollment:
Participant gender:
Summary
This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers. The study will enrol approximately 72 subjects at one clinical study center in the United States.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline